Safety and sustained benefits of Adempas® from Bayer confirmed by results of long-term studies
- Details
- Category: Bayer
Data presented at the European Respiratory Society (ERS) Congress today confirm the safety profile and the sustained efficacy of Adempas® (riociguat) over at least two years of treatment in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment, and in patients with pulmonary arterial hypertension (PAH).
AstraZeneca and Redx Pharma agree research collaboration
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into a research collaboration with Redx Pharma Limited to discover and develop new molecules targeting a genetic driver of tumour growth and survival. The research will complement AstraZeneca's strategic approach focused on genetic drivers of cancer and mechanisms of resistance to established and novel cancer therapies.
Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
- Details
- Category: Novartis
At the European Society of Cardiology congress and published simultaneously in the New England Journal of Medicine, Novartis revealed that its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in the largest heart failure study ever done[1],[6].
New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
- Details
- Category: AstraZeneca
AstraZeneca has announced the results of the Phase IV ATLANTIC study, which indicates that the profile of BRILINTA/BRILIQUE™ (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients.
Ebola vaccine trials fast-tracked by international consortium
- Details
- Category: GlaxoSmithKline
A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in west Africa.
Pfizer and Merck to collaborate on study evaluating novel anti-cancer combination regimen
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's crizotinib (XALKORI®) with Merck's investigational anti-PD-1 antibody pembrolizumab,
Roche and InterMune reach definitive merger agreement
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 8.3 billion on a fully diluted basis.
More Pharma News ...
- Novartis provides drug candidate compounds to TB Alliance
- United States Department of Justice closes investigation into PLATO clinical trial for Brilinta
- FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer
- Sanofi and MannKind announce global licensing agreement for Afrezza® (insulin human) rapid-acting inhaled insulin
- Allied Minds and Bristol-Myers Squibb form new enterprise
- Roche to acquire Santaris Pharma to expand discovery and development of RNA-targeting medicines
- Pfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines